Loading
The small Chinese trial whose startling response rates at ASCO 2017 drew Johnson and Johnson to Legend Biotech and became the myeloma CAR-T Carvykti.
57 patients treated at Xi'an Jiaotong University's Second Affiliated Hospital (Journal of Hematology and Oncology 2018): objective response 88%, complete response 68%, median progression-free survival 15 months, manageable cytokine release syndrome; a further 17 patients were treated at three other sites. Presented at ASCO 2017 by Fan Xiaohu and Zhao Wanhong, it led to the December 2017 Janssen collaboration ($350 million upfront) and to CARTITUDE-1, FDA approval as ciltacabtagene autoleucel in 2022 and NMPA approval in 2024. The clearest case of a Chinese academic-industry cell therapy becoming a global standard.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.